Post
Regeneron’s gene therapy triumphs twice, restoring hearing in children
Regeneron Pharmaceuticals’ gene therapy for otoferlin hearing loss, DB-OTO, has restored hearing to normal in an 11-month-old child within 24 …
Regenex Bio eyes FDA meeting to confirm pivotal DMD trial
Regenex Bio has announced it is meeting with the US Food and Drug Administration (FDA) with plans to initiate a …
Acepodia reports preliminary results from ACE1831 Phase I trial
Clinical-stage biotechnology company Acepodia has reported preliminary results from the Phase I study of anti-CD20 antibody conjugated allogeneic gamma delta …
Teva and Medincell report positive data for TEV-‘749 in schizophrenia trial
Teva and Medincell have announced positive results from the Phase III Subcutaneous OLAnzapine Extended-Release Injection Study (SOLARIS) trial’s efficacy portion …
NeuShen begins dosing for Phase I trial of schizophrenia treatment
NeuShen Therapeutics has dosed the first healthy volunteer in Australia, marking the start of a Phase I first-in-human clinical trial …
Teva and Medincell report positive data for TEV-‘749 in schizophrenia trial
Teva and Medincell have announced positive results from the Phase III Subcutaneous OLAnzapine Extended-Release Injection Study (SOLARIS) trial’s efficacy portion …
NeuShen begins dosing for Phase I trial of schizophrenia treatment
NeuShen Therapeutics has dosed the first healthy volunteer in Australia, marking the start of a Phase I first-in-human clinical trial …
Phanes Therapeutics signs clinical supply agreement with Roche
US-based biopharmaceutical company Phanes Therapeutics has announced a clinical supply agreement with Roche for a combination therapy study. The collaboration will …
ESCMID 2024: Long-acting injectables for HIV prevention
At the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global (formerly ECCMID) conference in Barcelona, Spain, the …
UK report warns that economic instability is threatening life sciences sector
A report published by Medicines Discovery Catapult (MDC) is urging the UK life sciences sector to boost investment following findings …
Zenas raises $200m to advance autoimmune antibody therapy
US-based Zenas BioPharma has raised $200m in a Series C round to support the clinical development of its lead candidate, …
OCT Europe: Data governance guidance provides much-needed clarity
The introduction of a section dedicated to data governance in the European good clinical practice (GCP) guidance provides much-needed clarity. In …
Uproleselan’s failed Phase III AML trial shakes up GlycoMimetics’ future
On 6 May 2024, US-based biotech GlycoMimetics announced that its E-selectin inhibitor candidate uproleselan had failed to improve the overall …
Pfizer reports fatality in Phase II DMD gene therapy study
Pfizer has reported the death of a patient in the Phase II DAYLIGHT study of experimental gene therapy, fordadistrogene movaparvovec, …
Neurogene reports initial data from Rett syndrome gene therapy trial
Neurogene has shared initial safety and tolerability results from its ongoing Phase I/II clinical trial of NGN-401, a gene therapy …